



**BIOCRYST**

**HAE**

**FELLOWSHIP**

**PROGRAM**

**At BioCryst, we are committed to advancing research, innovation, and training for healthcare professionals.**

We are excited to begin accepting applications for the 2024 HAE Fellowship Program, which will support third-year fellowship candidates completing independent research focused on hereditary angioedema (HAE) at accredited, US-based academic institutions. Clinical training may be included in the program but is not required.



Learn more about the fellowship program on the following pages

**BIOCRYST**

**HAE**

**FELLOWSHIP**

**PROGRAM**

## **ELIGIBILITY CRITERIA**

Third-year fellowship candidates completing independent HAE-focused research at an accredited, US-based academic institution are eligible to apply.

The following research is **not** eligible for inclusion:

- Research involving the study of any pharmaceutical product
- Basic science or fundamental research (in animal model, *in vitro*, etc)

---

**Note:** *No aspect of the fellowship program may benefit BioCryst's business or assets.*

## **FUNDING**

Grant funding is available to support 1 fellow for up to 1 year at \$80,000 USD. The budget may include salary and support of fellow benefits. Funding may not be used for overhead or indirect costs. Funds will be awarded to the academic institution.



## HOW TO APPLY

Applications may be submitted starting **November 9, 2023**.

→ To access the application form please visit <https://www.biocryst.com/science/external-research-program/> or scan the QR code



→ Application forms (including required attachments) may be submitted via email to [grants@biocryst.com](mailto:grants@biocryst.com)

→ For further information, please contact [grants@biocryst.com](mailto:grants@biocryst.com)



## KEY DATES

→ **Application window opens:** November 9, 2023

→ **Full proposal deadline:** February 15, 2024 23:59 EST (New York, GMT-5)

→ **BioCryst review of proposals:** March 2024

→ **Notification of decision:** April 2024

→ **Anticipated earliest project start date:** June 2024



OUR AREAS OF

# INTEREST

## DEFINING

overall disease burden for patients, families, and others impacted by HAE/bradykinergic angioedema

- Understanding HAE disease and treatment burden on quality of life (including physical and mental health impacts) on patients and caregivers
- Healthcare utilization costs and financial burden of HAE
- Evolution of understanding and classification of bradykinergic angioedema syndromes (ie, C1-inHAE, hereditary, acquired, contact pathway mutations)

## REDEFINING

HAE/bradykinergic angioedema disease management goals and optimal outcomes

- Diagnosis, management, and outcome measures of success for patients living with HAE/bradykinergic angioedema (including optimal mental health outcomes)
- Individualizing support and shared decision making to improve patient experience and long-term goals for success
- Diagnosis and management of pediatric patients with HAE/bradykinergic angioedema

